https://www.selleckchem.com/pr....oducts/dl-ap5-2-apv.
This trial was conducted to compare the efficacy of low dose once-a-week cisplatin and once-every-3-weeks cisplatin with radiation in locally advanced head and neck squamous cell carcinoma (LAHNSCC). The current analysis focuses on the quality of life (QoL) of patients in this trial. In this phase III randomized trial, patients with nonmetastatic LAHNSCC were randomized to receive cisplatin 30mg/m once-a-week or 100mg/m once every- 3-weeks concurrently with radiotherapy. The primary endpoint was locoregional control. QoL was a key
Like
Comment
Share
